Business Wire

ADVA posts strongest Q1 results in company’s history

Share

ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported record financial results for Q1 2021 ended on March 31, 2021. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005956/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brian Protiva, CEO, ADVA (Photo: Business Wire)

Q1 2021 financial summary1

(in thousands of EUR)

   

Q1

     

Q1

     

Change

     

Q4

     

Change

 

 

   

2021

     

2020

     

 

     

2020

     

 

 

 

 

Revenues

   

144,473

     

132,686

     

8.9%

     

140,572

     

2.8%

 

Pro forma gross profit

   

55,345

     

42,275

     

30.9%

     

54,641

     

1.3%

 

in % of revenues

   

38.3%

     

31.9%

     

6.4pp

     

38.9%

     

-0.6pp

 

Pro forma operating income

   

12,860

     

-1,671

     

869.6%

     

14,343

     

-10.3%

 

in % of revenues

   

8.9%

     

-1.3%

     

10.2pp

     

10.2%

     

-1.3pp

 

Operating income (loss)

   

11,573

     

-4,038

     

386.6%

     

13,085

     

-11.6%

 

Net income

   

11,228

     

-7,235

     

255.2%

     

13,249

     

-15.3%

 

 

(in thousands of EUR)

   

Mar. 31

2021

     

Mar. 31

2020

     

Change

     

Dec. 31

2020

     

Change

 

Cash and cash equivalents

   

79,060

     

52,753

     

49.9%

     

64,881

     

21.9%

 

Net debt

   

10,626

     

67,705

     

-84.3%

     

25,545

     

-58.4%

 

Net working capital

   

125,785

     

134,219

     

-6.3%

     

129,853

     

-3.1%

 

1 Potential difference due to rounding

Q1 2021 IFRS financial results
Revenues in Q1 2021 reached EUR 144.5 million, up by 2.8% from EUR 140.6 million in Q4 2020, also up by 8.9% compared to EUR 132.7 million in the same year-ago period, and are within the guidance corridor of between EUR 143 million and EUR 148 million. This success was particularly due to high order volume from network operators as well as private companies and governments.

Pro forma gross profit in Q1 2021 increased by 1.3%, reaching EUR 55.3 million (38.3% of revenues) compared to EUR 54.6 million (38.9% of revenues) in Q4 2020 and increased significantly by 30.9% compared to EUR 42.3 million reported in the year-ago quarter. Orders for network synchronization technology again developed positively in Q1. In addition, the customer mix contributed positively to the margin increase in the past quarter.

Pro forma operating income for Q1 2021 was EUR 12.9 million (8.9% of revenues) and decreased by 10.3% compared to EUR 14.3 million (10.2% of revenues) reported in Q4 2020. Compared to the year-ago quarter, pro forma operating income improved significantly by 869.6% from a loss of EUR 1.7 million (-1.3% of revenues). Hence the pro forma operating margin was at the top end of the guidance corridor of 7% to 9%. In addition to the higher gross profit, this substantial margin improvement is mainly due to improved operational expenditures.

Operating income for Q1 2021 of EUR 11.6 million decreased by 11.6% from EUR 13.1 million reported for Q4 2020 and significantly increased by 386.6% from a loss of EUR 4.0 million in the same year-ago quarter.

Net income reached EUR 11.2 million in Q1 2021, down by 15.3% from EUR 13.2 million in Q4 2020, and significantly up by 255.2% from a loss of EUR 7.2 million in Q1 2020.

The company’s cash and cash equivalents totaled EUR 79.1 million, representing an increase of EUR 14.2 million compared to EUR 64.9 million at the end of Q4 2020. Year-over-year cash and cash equivalents substantially increased by EUR 26.3 million from EUR 52.7 million at the end of Q1 2020. The higher cash balance is mainly the result of the improved profitability and lower capital expenditures, particularly compared to the prior-year quarter.

Consequently, net debt in Q1 2021 strongly decreased by EUR 14.9 million to EUR 10.6 million from EUR 25.5 million at the end of Q4 2020 and improved significantly by EUR 57.1 million compared to Q1 2020 (EUR 67.7 million).

Net working capital at quarter-end was EUR 125.8 million and decreased by EUR 4.1 million compared to EUR 129.9 million at the end of Q4 2020.

Management commentary
“Today we report the best Q1 in our long history as a publicly listed company. We’ve never posted higher revenues in the first quarter of a financial year, and we’ve never achieved higher profitability, generated more cash, or recorded a better order intake,” commented Brian Protiva, CEO, ADVA. “The speed of digitization in many countries has increased noticeably and we are seeing very good demand from all of our customer groups. At the same time, we are making good progress with the transformation of our business. Focus on growth markets with a higher proportion of software and services as well as more verticalization will bring our pro forma EBIT to around 10% of revenues.”

“Our transformation strategy combined with strict cost control showed the expected effects and have opened the door to sustainably higher margin potential. Net income of EUR 11.2 million is already over 50% of the result generated in 2020. With that, we have made an excellent start to the new financial year,” said Uli Dopfer, CFO, ADVA. “We were able to further increase cash and reduce net debt to EUR 10.6 million. This further underlines our strong financial position.”

Financial outlook 2021
For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 6.0% and 10.0% of revenues.

The company will publish its financial results for Q2 2021 on July 22, 2021.

Conference call details
ADVA will hold a conference call for analysts and investors today, April 22, 2021, to discuss the Q1 2021 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CEST (9:00 a.m. EDT). A question and answer session will follow management presentations.

A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

The complete quarterly statement 3M 2021 (January – March) is available as a PDF:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements

A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls

Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.

Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Steven Williams
t +49 89 890 66 59 18
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release

Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk

World First: H-UKR 0% Clinker Cement Obtains Technical Assessment (ATec) for Wind Turbine Foundations22.10.2025 09:00:00 EEST | Press release

Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, today announces that it has obtained a Technical Assessment (ATec) validating the use of its H-UKR decarbonized cement for wind turbine foundations. This unprecedented recognition, a world first for a 0% clinker cement, certifies that the H-UKR solution meets the highest standards of sustainability, safety, and performance for particularly rigorous applications such as wind power. A strategic step towards new markets This certification marks another key milestone for Hoffmann Green, enabling it to further accelerate its growth in the renewable energy market from 2026 and beyond. Obtaining this ATec certification paves the way for new commercial opportunities in this sector, strengthening its insurability with project owners

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 03:25:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are energized by the progress made by Innovent to date and look forward to collaborating to unlock the potential of t

YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 22:16:00 EEST | Press release

Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s

Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 22:09:00 EEST | Press release

Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection and communication.” The integration of location intelligence into census

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye